-
Tetra Bio-Pharma Opens New Subsidiary In Australia And Provides Regulatory Update
Monday, June 6, 2022 - 10:10am | 551Tetra Bio-Pharma Inc. (TSX:TBP) (OTCQB: TBPMF) (FRA:JAM1) launched new wholly owned subsidiary 'Tetra Bio-Pharma Australia Pty Ltd', an Australian-based research company focused on the execution of clinical trials in Australia. This represents Tetra's second foreign subsidiary and is in...
-
Tetra Bio-Pharma And Cannvalate Enter Into Partnership
Thursday, May 5, 2022 - 10:55am | 587Tetra Bio-Pharma Inc. (OTCQB: TBPMF) (TSX:TBP) (FRA:JAM1) has entered into a research and development agreement with Cannvalate Pty Ltd for the initiation of the REBORN, PLENITUDE and CAUMZ clinical trials in Australia, and a subscription agreement contemplating a private placement of common shares...
-
Tetra Bio-Pharma: Positive Clinical Data From Both Phase 2 Clinical Trials Of QIXLEEF For Cancer Pain
Monday, November 29, 2021 - 6:45pm | 380Tetra Bio-Pharma Inc. (TSX: TBP) (OTCQB: TBPMF), a leader in cannabinoid-derived drug discovery and development announced on Monday that it produced positive initial clinical data from its ongoing Phase 2 clinical trials of QIXLEEF™ (REBORN©1 and PLENITUDE©), which is...